Arthur T Knackerbracket has found the following story:
About one in three diabetic patients develops diabetic retinopathy (DR), which can impair vision and lead to blindness. A new study in The American Journal of Pathology, published by Elsevier, provides clear evidence that high glucose increases the levels of enzymatic precursor -- lysyl oxidase propeptide (LOX-PP) -- that promotes cell death, which was verified in an animal model of diabetes. These findings may help develop novel DR treatments by targeting LOX-PP or its metabolites.
'We found that hyperglycemic and diabetic conditions increased LOX-PP levels," explained lead investigator Sayon Roy, PhD, of the Departments of Medicine and Ophthalmology at Boston University School of Medicine, Boston, MA, USA. "LOX-PP may induce cell death by compromising a cell survival pathway, and in retinas of diabetic rats, increased LOX-PP contributed to retinal vascular cell death associated with DR. Administration of recombinant LOX-PP alone was sufficient to induce cell death. This report shows novel functionality of LOX-PP in mediating cell death under high glucose condition in retinal endothelial cells as well as in diabetic animals."
Studies in pancreatic and breast cancer cells suggest that LOX-PP overexpression may trigger cell death. The researchers therefore studied the role of LOX-PP in the retinal tissue. The retinal blood vessels of normal and diabetic rats and normal rats administered artificially synthesized LOX-PP (recombinant LOX-PP, rLOX-PP) directly into the eye, were examined. Changes associated with DR such as swelling, blood vessel leakage, blockage or thickening of vascular walls, and histologic indicators such as acellular capillaries (AC) and pericyte loss (PL) were studied.
More AC and PL were observed in the retinas of diabetic rats compared to controls. In non-diabetic rats, injection of rLOX-PP directly into the eye also increased the number of ACs and PLs compared to rats receiving a control injection.
-- submitted from IRC
(Score: 2) by barbara hudson on Friday September 20 2019, @07:10PM
The second is to lower the oxygen demand of the retina by destroying a fair chunk of it. Laser scarring by laying a pattern of laser burns around the periphery of the retina tried to save central vision by reducing invasive growth of blood vessels on the surface of the retina (pan-retinal photo coagulation, or PRP).
Both have side effects.
Enzymes that are byproducts of cell death won't change blood vessels growing on the surface of the retina. It might help with other retinal diseases, but unless it kills off blood vessels on the surface of the retina without killing anything else, it's of no use in treating DR, since DR doesn't directly cause cell death, and even completely stopping cell death won't prevent blood vessels growing on the surface of the retina.
Sounds more like a discovery looking for a disease than any real breakthrough.
SoylentNews is social media. Says so right in the slogan. Soylentnews is people, not tech.